Genentech/Roche’s Avastin Makes Progress In Phase III Breast Cancer Trials
Studies bode well for new indications, but side effects and high cost present potential barriers to use.
More from Archive
More from Pink Sheet
Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions
• By
The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.
• By
Pink Sheet Drug Review Profile feature listing FDA staff who conducted the reviews of Novavax and Moderna's post-pandemic COVID-19 vaccines
• By
Business Group on Health annual employer survey highlights fast-growing Rx costs, led by the GLP-1 drugs, and payer strategies for controlling them. Policy prescriptions are unclear, though, since employers are loath to leave PBMs and nervous about pending changes to Medicare and Medicaid.